Hodi, F. S., Chiarion-Sileni, V., Gonzalez, R., Grob, J., Rutkowski, P., Cowey, C. L., Lao, C. D., Schadendorf, D., Wagstaff, J., Dummer, R., Ferrucci, P. F., Smylie, M., Hill, A., Hogg, D., Marquez-Rodas, I., Jiang, J., Rizzo, J., Larkin, J., & Wolchok, J. D. (2018). nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. Lancet oncology, 19(11), 1480–1492. http://access.bl.uk/ark:/81055/vdc_100071726552.0x00001c